Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Xenomics, Inc.
Editorial Article in the Clinical Chemistry Highlights Significant Progress in Optimization of the Non-Invasive Transrenal DNA Technology Reported by Xenomics
March 10th, 2009
Xenomics, Inc. (Pink Sheets: XNOM), a developer of proprietary, non-invasive nucleic acid based molecular diagnostics, announces that the Clinical Chemistry published an editorial entitled “On Targeting Cell-Free DNA in Urine: A Protocol for Optimized DNA Analysis” on February 20th in its early online edition. The editorial provides an overview of the progress made in the area of testing for cell-free DNA in urine starting from pioneering work published by Xenomics’ scientists in 2000, and discusses the latest paper “Optimization of Transrenal DNA Analysis: Detection of Fetal DNA in Maternal Urine” published by Xenomics in Clinical Chemistry on January 30th, 2009. The...
Source: Cancer Weekly (2009-03-10)
|
